Oruka Therapeutics Prices Upsized $700M Offering at $72.50/Share After Positive Trial Data
ORKA has more than doubled off its 52-week low of $8.91 on elevated volume (3.3× avg).
Summary
Oruka Therapeutics has priced its upsized underwritten public offering, raising approximately $700.4 million in gross proceeds by selling 9,660,000 shares at $72.50 per share. This final pricing confirms an increase from the previously proposed $500 million offering announced yesterday, which followed highly positive Phase 2a clinical trial results for ORKA-001. While the significant capital infusion provides Oruka with substantial resources to advance its pipeline, particularly ORKA-001, the offering is highly dilutive to existing shareholders, especially given the pricing below the current market value. Traders will be closely watching the market's reaction to this dilution and the company's strategic use of the new capital.
At the time of this announcement, ORKA was trading at $74.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $8.91 to $91.00. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.